Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld, AnnMarie Liapakis, Marcelo Silva, Howard Monsour, Paul Martin, Stanislas Pol, Maria Carlota Londoño, Tarek Hassanein, Philippe J. Zamor, Eli Zuckerman, Shuyan Wan, Beth Jackson, Bach Yen Nguyen, Michael Robertson, Eliav Barr, Janice Wahl, Wayne Greaves

Research output: Contribution to journalArticle

400 Citations (Scopus)

Abstract

BACKGROUND: Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.

METHODS: In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done centrally with an interactive voice response system. An additional cohort of patients who were not randomised received the same regimen open-label and underwent intensive pharmacokinetic sampling. The primary efficacy outcome was a non-randomised comparison of sustained virological response at 12 weeks (SVR12) after the end of therapy for the combined immediate treatment group and the pharmacokinetic population with a historical control. The primary safety outcome was a randomised comparison between the immediate treatment group and the deferred treatment group. After 4 weeks of follow-up (study week 16), unmasking occurred and patients in the deferred treatment group received grazoprevir and elbasvir. The primary efficacy hypothesis was tested at a two-sided significance level (type I error) of 0·05 using an exact test for a binomial proportion. Safety event rates were compared between immediate treatment and deferred treatment groups using the stratified Miettinen and Nurminen method with baseline dialysis status as the strata. The study is registered at ClinicalTrials.gov, number NCT02092350.

FINDINGS: 224 patients were randomly assigned to the immediate treatment group with grazoprevir and elbasvir (n=111) or the deferred treatment group (n=113), and 11 were assigned to the intensive pharmacokinetic population. Overall, 179 (76%) were haemodialysis-dependent, 122 (52%) had HCV genotype 1a infection, 189 (80%) were HCV treatment-naive, 14 (6%) were cirrhotic, and 108 (46%) were African American. Of the 122 patients receiving grazoprevir and elbasvir, six were excluded from the primary efficacy analysis for non-virological reasons (death, lost-to-follow-up [n=2], non-compliance, patient withdrawal, and withdrawal by physician for violent behaviour). No patients in the combined immediate treatment group and intensive pharmacokinetic population and five (4%) in the deferred treatment group discontinued because of an adverse event. Most common adverse events were headache, nausea, and fatigue, occurring at similar frequencies in patients receiving active and placebo drugs. SVR12 in the combined immediate treatment group and intensive pharmacokinetic population was 99% (95% CI 95·3-100·0; 115/116), with one relapse 12 weeks after end of treatment when compared with a historical control of 45%, based on meta-analyses of interferon-based regimens used in clinical trials of patients infected with HCV who are on haemodialysis.

INTERPRETATION: Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease.

FUNDING: Merck Sharp & Dohme Corp.

Original languageEnglish (US)
Pages (from-to)1537-1545
Number of pages9
JournalThe Lancet
Volume386
Issue number10003
DOIs
StatePublished - Oct 17 2015

Fingerprint

Chronic Renal Insufficiency
Hepacivirus
Genotype
Infection
Therapeutics
Pharmacokinetics
Renal Dialysis
MK-5172
2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole
Safety
Placebos
Population
Ribavirin
Lost to Follow-Up
Chronic Hepatitis C
Virus Diseases
Patient Compliance
Hepatitis C
Random Allocation
Protease Inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) : a combination phase 3 study. / Roth, David; Nelson, David R.; Bruchfeld, Annette; Liapakis, AnnMarie; Silva, Marcelo; Monsour, Howard; Martin, Paul; Pol, Stanislas; Londoño, Maria Carlota; Hassanein, Tarek; Zamor, Philippe J.; Zuckerman, Eli; Wan, Shuyan; Jackson, Beth; Nguyen, Bach Yen; Robertson, Michael; Barr, Eliav; Wahl, Janice; Greaves, Wayne.

In: The Lancet, Vol. 386, No. 10003, 17.10.2015, p. 1537-1545.

Research output: Contribution to journalArticle

Roth, D, Nelson, DR, Bruchfeld, A, Liapakis, A, Silva, M, Monsour, H, Martin, P, Pol, S, Londoño, MC, Hassanein, T, Zamor, PJ, Zuckerman, E, Wan, S, Jackson, B, Nguyen, BY, Robertson, M, Barr, E, Wahl, J & Greaves, W 2015, 'Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study', The Lancet, vol. 386, no. 10003, pp. 1537-1545. https://doi.org/10.1016/S0140-6736(15)00349-9
Roth, David ; Nelson, David R. ; Bruchfeld, Annette ; Liapakis, AnnMarie ; Silva, Marcelo ; Monsour, Howard ; Martin, Paul ; Pol, Stanislas ; Londoño, Maria Carlota ; Hassanein, Tarek ; Zamor, Philippe J. ; Zuckerman, Eli ; Wan, Shuyan ; Jackson, Beth ; Nguyen, Bach Yen ; Robertson, Michael ; Barr, Eliav ; Wahl, Janice ; Greaves, Wayne. / Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) : a combination phase 3 study. In: The Lancet. 2015 ; Vol. 386, No. 10003. pp. 1537-1545.
@article{a51761b460564552acd7d5851b06f1e3,
title = "Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study",
abstract = "BACKGROUND: Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.METHODS: In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done centrally with an interactive voice response system. An additional cohort of patients who were not randomised received the same regimen open-label and underwent intensive pharmacokinetic sampling. The primary efficacy outcome was a non-randomised comparison of sustained virological response at 12 weeks (SVR12) after the end of therapy for the combined immediate treatment group and the pharmacokinetic population with a historical control. The primary safety outcome was a randomised comparison between the immediate treatment group and the deferred treatment group. After 4 weeks of follow-up (study week 16), unmasking occurred and patients in the deferred treatment group received grazoprevir and elbasvir. The primary efficacy hypothesis was tested at a two-sided significance level (type I error) of 0·05 using an exact test for a binomial proportion. Safety event rates were compared between immediate treatment and deferred treatment groups using the stratified Miettinen and Nurminen method with baseline dialysis status as the strata. The study is registered at ClinicalTrials.gov, number NCT02092350.FINDINGS: 224 patients were randomly assigned to the immediate treatment group with grazoprevir and elbasvir (n=111) or the deferred treatment group (n=113), and 11 were assigned to the intensive pharmacokinetic population. Overall, 179 (76{\%}) were haemodialysis-dependent, 122 (52{\%}) had HCV genotype 1a infection, 189 (80{\%}) were HCV treatment-naive, 14 (6{\%}) were cirrhotic, and 108 (46{\%}) were African American. Of the 122 patients receiving grazoprevir and elbasvir, six were excluded from the primary efficacy analysis for non-virological reasons (death, lost-to-follow-up [n=2], non-compliance, patient withdrawal, and withdrawal by physician for violent behaviour). No patients in the combined immediate treatment group and intensive pharmacokinetic population and five (4{\%}) in the deferred treatment group discontinued because of an adverse event. Most common adverse events were headache, nausea, and fatigue, occurring at similar frequencies in patients receiving active and placebo drugs. SVR12 in the combined immediate treatment group and intensive pharmacokinetic population was 99{\%} (95{\%} CI 95·3-100·0; 115/116), with one relapse 12 weeks after end of treatment when compared with a historical control of 45{\%}, based on meta-analyses of interferon-based regimens used in clinical trials of patients infected with HCV who are on haemodialysis.INTERPRETATION: Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease.FUNDING: Merck Sharp & Dohme Corp.",
author = "David Roth and Nelson, {David R.} and Annette Bruchfeld and AnnMarie Liapakis and Marcelo Silva and Howard Monsour and Paul Martin and Stanislas Pol and Londo{\~n}o, {Maria Carlota} and Tarek Hassanein and Zamor, {Philippe J.} and Eli Zuckerman and Shuyan Wan and Beth Jackson and Nguyen, {Bach Yen} and Michael Robertson and Eliav Barr and Janice Wahl and Wayne Greaves",
year = "2015",
month = "10",
day = "17",
doi = "10.1016/S0140-6736(15)00349-9",
language = "English (US)",
volume = "386",
pages = "1537--1545",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10003",

}

TY - JOUR

T1 - Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study)

T2 - a combination phase 3 study

AU - Roth, David

AU - Nelson, David R.

AU - Bruchfeld, Annette

AU - Liapakis, AnnMarie

AU - Silva, Marcelo

AU - Monsour, Howard

AU - Martin, Paul

AU - Pol, Stanislas

AU - Londoño, Maria Carlota

AU - Hassanein, Tarek

AU - Zamor, Philippe J.

AU - Zuckerman, Eli

AU - Wan, Shuyan

AU - Jackson, Beth

AU - Nguyen, Bach Yen

AU - Robertson, Michael

AU - Barr, Eliav

AU - Wahl, Janice

AU - Greaves, Wayne

PY - 2015/10/17

Y1 - 2015/10/17

N2 - BACKGROUND: Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.METHODS: In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done centrally with an interactive voice response system. An additional cohort of patients who were not randomised received the same regimen open-label and underwent intensive pharmacokinetic sampling. The primary efficacy outcome was a non-randomised comparison of sustained virological response at 12 weeks (SVR12) after the end of therapy for the combined immediate treatment group and the pharmacokinetic population with a historical control. The primary safety outcome was a randomised comparison between the immediate treatment group and the deferred treatment group. After 4 weeks of follow-up (study week 16), unmasking occurred and patients in the deferred treatment group received grazoprevir and elbasvir. The primary efficacy hypothesis was tested at a two-sided significance level (type I error) of 0·05 using an exact test for a binomial proportion. Safety event rates were compared between immediate treatment and deferred treatment groups using the stratified Miettinen and Nurminen method with baseline dialysis status as the strata. The study is registered at ClinicalTrials.gov, number NCT02092350.FINDINGS: 224 patients were randomly assigned to the immediate treatment group with grazoprevir and elbasvir (n=111) or the deferred treatment group (n=113), and 11 were assigned to the intensive pharmacokinetic population. Overall, 179 (76%) were haemodialysis-dependent, 122 (52%) had HCV genotype 1a infection, 189 (80%) were HCV treatment-naive, 14 (6%) were cirrhotic, and 108 (46%) were African American. Of the 122 patients receiving grazoprevir and elbasvir, six were excluded from the primary efficacy analysis for non-virological reasons (death, lost-to-follow-up [n=2], non-compliance, patient withdrawal, and withdrawal by physician for violent behaviour). No patients in the combined immediate treatment group and intensive pharmacokinetic population and five (4%) in the deferred treatment group discontinued because of an adverse event. Most common adverse events were headache, nausea, and fatigue, occurring at similar frequencies in patients receiving active and placebo drugs. SVR12 in the combined immediate treatment group and intensive pharmacokinetic population was 99% (95% CI 95·3-100·0; 115/116), with one relapse 12 weeks after end of treatment when compared with a historical control of 45%, based on meta-analyses of interferon-based regimens used in clinical trials of patients infected with HCV who are on haemodialysis.INTERPRETATION: Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease.FUNDING: Merck Sharp & Dohme Corp.

AB - BACKGROUND: Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.METHODS: In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done centrally with an interactive voice response system. An additional cohort of patients who were not randomised received the same regimen open-label and underwent intensive pharmacokinetic sampling. The primary efficacy outcome was a non-randomised comparison of sustained virological response at 12 weeks (SVR12) after the end of therapy for the combined immediate treatment group and the pharmacokinetic population with a historical control. The primary safety outcome was a randomised comparison between the immediate treatment group and the deferred treatment group. After 4 weeks of follow-up (study week 16), unmasking occurred and patients in the deferred treatment group received grazoprevir and elbasvir. The primary efficacy hypothesis was tested at a two-sided significance level (type I error) of 0·05 using an exact test for a binomial proportion. Safety event rates were compared between immediate treatment and deferred treatment groups using the stratified Miettinen and Nurminen method with baseline dialysis status as the strata. The study is registered at ClinicalTrials.gov, number NCT02092350.FINDINGS: 224 patients were randomly assigned to the immediate treatment group with grazoprevir and elbasvir (n=111) or the deferred treatment group (n=113), and 11 were assigned to the intensive pharmacokinetic population. Overall, 179 (76%) were haemodialysis-dependent, 122 (52%) had HCV genotype 1a infection, 189 (80%) were HCV treatment-naive, 14 (6%) were cirrhotic, and 108 (46%) were African American. Of the 122 patients receiving grazoprevir and elbasvir, six were excluded from the primary efficacy analysis for non-virological reasons (death, lost-to-follow-up [n=2], non-compliance, patient withdrawal, and withdrawal by physician for violent behaviour). No patients in the combined immediate treatment group and intensive pharmacokinetic population and five (4%) in the deferred treatment group discontinued because of an adverse event. Most common adverse events were headache, nausea, and fatigue, occurring at similar frequencies in patients receiving active and placebo drugs. SVR12 in the combined immediate treatment group and intensive pharmacokinetic population was 99% (95% CI 95·3-100·0; 115/116), with one relapse 12 weeks after end of treatment when compared with a historical control of 45%, based on meta-analyses of interferon-based regimens used in clinical trials of patients infected with HCV who are on haemodialysis.INTERPRETATION: Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease.FUNDING: Merck Sharp & Dohme Corp.

UR - http://www.scopus.com/inward/record.url?scp=84947338288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947338288&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(15)00349-9

DO - 10.1016/S0140-6736(15)00349-9

M3 - Article

C2 - 26456905

AN - SCOPUS:84947338288

VL - 386

SP - 1537

EP - 1545

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10003

ER -